Hepatitis B virus core and e antigen: Immune recognition and use as a vaccine carrier moiety

被引:25
|
作者
Schodel, F
Peterson, D
Milich, D
机构
[1] VIRGINIA COMMONWEALTH UNIV, DEPT BIOCHEM, RICHMOND, VA USA
[2] Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA
关键词
HBeAg; HBcAg; hepatitis B virus; core particles; epitope presentation; malaria; circumsporozoite antigen; malaria vaccine;
D O I
10.1159/000150481
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The hepatitis B virus (HBV) core gene codes for two partially colinear antigens: a secreted antigen (HBeAg) and the particulate core antigen (HBcAg), which assembles to form subviral particles and in virions contains the viral genome and polymerase, In this review we summarize data on the immune recognition of HBc/eA and recent progress in the use of HBcAg as a carrier moiety for heterologous epitopes. During HBV infection, HBcAg and HBcAg are important targets of antiviral immunity, HBcAg and HBeAg are serologically distinct but share all characterized T-cell epitopes. The particulate HBcAg can elicit T-cell-independent as well as T-cell-dependent antibody responses. HBeAg is a strictly T-cell-dependent antigen. Neonatal tolerance to maternally derived circulating HBcAg may facilitate chronic HBV infection after vertical transmission of HBV. In a murine transgenic model, HBc/eAg-specific Th1 cells were more readily anergized, whereas Th2 cells more easily escaped tolerization, In human HBV infection, acute adult HBV infection with subsequent virus elimination was characterized by Th1-like alpha-HBV serum Ige subtype distribution, whereas a Th2-like distribution of IgG subtypes was observed during chronic infection. During chronic infection, core gene mutants which abolish HBeAg synthesis were frequently observed. To exploit the unusual immunogenicity of particulate HBcAg as a vaccine carrier moiety, insertion sites for foreign epitopes were defined in recombinant expression systems, While fusion of epitopes to the N-terminus required a linker sequence for surface accessibility both fusion to the N-terminus and to the C-terminus was compatible with particle assembly and preserved the native antigenicity and immunogenicity of HBcAg. Epitope insertion at an immunodominant internal site of HBcAg reduced the HBcAg immunogenicity and antigenicity and most drastically enhanced the immunogenicity of the inserted foreign epitopes. This internal site of HBcAg was used to express circumsporozoite antigen (CS) repeat epitopes of two rodent malaria parasites and of Plasmodium falciparum. Purified hybrid HBcAg-CS proteins were particulate and displayed CS antigenicity as well as reduced native HBc antigenicity. Immunization of several mouse strains with HBcAg-CS hybrid particles resulted in high-titered serum anti-CS antibodies representing all murine IgG isotypes and protected BALB/c mice against plasmodial challenge, immunization of mice with HBcAg or HBcAg-CS particles formulated on alum, complete Freund's or incomplete Freund's adjuvant resulted in equivalent anti-CS and anti-HBc serum antibody titers, Preexisting immunity to HBcAg did not significantly alter the immunogenicity of hybrid HBeAg particles suggesting that carrier-specific immune suppression does not limit the use of hybrid HBcAg with internal insertions, Immunization with HBcAg-CS particles universally primed HBcAg-specific T cells and in addition CS-specific T cells were if the insert contained a CS-specific T-cell site for the corresponding murine MHC class II haplotype. The internal amino acid position in HBcAg is therefore permissive for the inclusion of heterologous T-helper as at ll as B-cell epitopes.
引用
收藏
页码:104 / 110
页数:7
相关论文
共 50 条
  • [1] Hybrid hepatitis B virus core antigen as a vaccine carrier moiety .1. Presentation of foreign epitopes
    Schodel, F
    Peterson, D
    Hughes, J
    Wirtz, R
    Milich, D
    JOURNAL OF BIOTECHNOLOGY, 1996, 44 (1-3) : 91 - 96
  • [3] Development of hepatitis C virus vaccine using hepatitis B core antigen as immuno-carrier
    Chen, Jia-Yu
    Li, Fan
    WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (48) : 7774 - 7778
  • [4] The core antigen of hepatitis B virus as a carrier for immunogenic peptides
    Murray, K
    Shiau, AL
    BIOLOGICAL CHEMISTRY, 1999, 380 (03) : 277 - 283
  • [5] Immune response to hepatitis B vaccine of subjects with isolated antibody to hepatitis B core antigen
    Tseng, KC
    Lei, HY
    Cheng, PN
    Young, KC
    Jen, CM
    Wu, CH
    Chang, TT
    HEPATO-GASTROENTEROLOGY, 2003, 50 (53) : 1474 - 1477
  • [6] HEPATITIS-B VIRUS CARRIER WITH LOW TITER OF ANTIBODY TO HEPATITIS-B CORE ANTIGEN
    NAITO, M
    MATSUDA, H
    OKUNO, H
    KIM, H
    AZUMA, M
    KASHIWAGI, T
    MITSUTANI, N
    KOIZUMI, T
    KAWAGUCHI, G
    KOBAYASHI, Y
    HEPATO-GASTROENTEROLOGY, 1994, 41 (03) : 235 - 238
  • [7] Immunogenicity of new DNA vaccine encoding for hepatitis B virus core antigen
    邢益平
    黄祖瑚
    王世霞
    蔡洁
    李军
    卢山
    中华肝脏病杂志, 2004, (06) : 23 - 25
  • [8] Cellular immune responses in hepatitis B virus e antigen negative chronic hepatitis B
    Vassilopoulos, D.
    Rapti, I.
    Nikolaou, M.
    Hadziyannis, E.
    Hadziyannis, S. J.
    JOURNAL OF VIRAL HEPATITIS, 2008, 15 (11) : 817 - 826
  • [9] THE HEPATITIS NUCLEOCAPSID AS A VACCINE CARRIER MOIETY
    MILICH, DR
    PETERSON, DL
    ZHENG, J
    HUGHES, JL
    WIRTZ, R
    SCHODEL, F
    COMBINED VACCINES AND SIMULTANEOUS ADMINISTRATION: CURRENT ISSUES AND PERSPECTIVES, 1995, 754 : 187 - 201
  • [10] PREVENTION OF PERINATAL TRANSMISSION OF HEPATITIS-B VIRUS (HBV) TO CHILDREN OF E-ANTIGEN-POSITIVE HBV CARRIER MOTHERS BY HEPATITIS-B IMMUNE GLOBULIN AND HBV VACCINE
    KANAI, K
    TAKEHIRO, A
    NOTO, H
    NISHIDA, M
    TAKAHASHI, K
    KAWASHIMA, Y
    IGARASHI, Y
    MATSUSHITA, K
    SHIMIZU, M
    JOURNAL OF INFECTIOUS DISEASES, 1985, 151 (02): : 287 - 290